Recent in vivo studies have also shown that after focal cerebral ischemia, activation of rho-kinase (ROCK) in ECs contributes to endothelial dysfunction and microcirculatory disturbances. 15 In vitro data also support activation of ROCK in ECs during experimental ischemia contributing to EC Objective-Sex differences in cerebral ischemic injury are, in part, arrtibutable to the differences in cerebrovascular perfusion. We determined whether the brain microvascular endothelial cells (ECs) isolated from the female brain are more resistant to ischemic injury compared with male ECs, and whether the difference is attributable to lower expression of soluble epoxide hydrolase and higher levels of vasoprotective epoxyeicosatrienoic acids (EETs). We also determined whether protection by EETs is linked to the inhibition of rho-kinase (ROCK). Methods and Results-EC ischemic damage was measured after oxygen-glucose deprivation (OGD) using propidium iodide (PI) and cleaved caspase-3 labeling. Expression of soluble epoxide hydrolase was determined by quantitative polymerase chain reaction and immunocytochemistry, EETs levels by liquid chromatography-tandem mass spectrometry, and ROCK activity by ELISA. EC damage was higher in males compared with females, which correlated with higher soluble epoxide hydrolase mRNA, stronger immunoreactivity, and lower EETs compared with female ECs. Inhibition of soluble epoxide hydrolase abolished the sex difference in EC damage. ROCK activity was higher in male versus female ECs after OGD, and sex differences in EC damage and ROCK activity were abolished by 14,15-EET and ROCK inhibition. Conclusion-Sex differences in ischemic brain injury are, in part, attributable to differences in EET-mediated inhibition of EC ROCK activation after ischemia. (Arterioscler Thromb Vasc Biol. 2012;32:1936-1942 .) The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
P remenopausal women have lower stroke risk and mortality compared with age-matched men. 1 The sex difference in susceptibility to ischemic injury is, in part, attributable to differences in vascular regulatory and protective mechanisms, in which the vascular endothelium is a key player. 2 Endothelial dysfunction has been observed in stroke patients and has been related to stroke pathophysiology, subtypes, clinical severity, and outcome. 3 Furthermore, there is growing appreciation of the role of endothelium in the recovery process after brain injury and as a therapeutic target in stroke. [4] [5] [6] Clinical studies suggested that endothelial function is improved in young women compared with age-matched men, 7, 8 and experimental studies demonstrated that sex differences in endothelial cell (EC) function contribute to differences in outcome after ischemic brain injury. 9 The mechanisms underlying the sex difference in EC function and susceptibility to ischemic injury are not fully understood.
Epoxyeicosatrienoic acids (EETs) are endothelium-derived P450 epoxygenase metabolites of arachidonic acid that exhibit multiple vasoprotective actions during cerebral ischemia, including vasodilation and suppression of postischemic inflammation. EETs have also been shown to protect coronary and pulmonary vascular ECs from hypoxic injury. 10, 11 The activity of EETs is regulated through their metabolism by soluble epoxide hydrolase (sEH), 12 an enzyme with greater expression in men compared with female cerebral vessels. 13 Lower levels of sEH lead to higher levels of circulating EETs and greater EET-mediated protection in women compared with men. 14 However, it is not clear whether sEH is lower in female cerebrovascular vessels than male cerebrovascular ECs and whether the difference contributes to differences in EC sensitivity to ischemic injury. Therefore, in the current study, we hypothesized that primary microvascular ECs isolated from the adult female mouse brain are more resistant to ischemic injury induced in vitro by oxygen-glucose deprivation (OGD) compared with male cells and that greater resistance to ischemic injury in female cerebrovascular ECs results from lower expression of sEH and consequently higher levels of vasoprotective EETs in female ECs compared with male ECs. injury and death. 16 Interestingly, EETs have been shown to suppress ROCK activation in pulmonary ECs. 17 Therefore, in our current study, we further hypothesized that the protective effect of EETs on cerebrovascular EC survival is mediated by inhibition of ROCK activation after OGD.
Materials and Methods
Studies were performed according to the National Institutes of Health Guidelines for the use and care of laboratory animals, and the protocols were approved by the Oregon Health and Science University Institutional Animal Care and Use Committee.
EC Culture
Primary mouse cerebral ECs were isolated from 8-week-old male and female C57BL6 mice (Charles River Laboratory, Wilmington, MA) based on the method described by Szabó et al. 18, 19 Briefly, cerebral cortices devoid of cerebella, white matter, large vessels, and leptomeninges were prepared by aseptic macroscopic dissection from the mouse brain and diced into small pieces. Cortices were then digested in 1 mg/mL collagenase (Worthington Biochemical Corporation, Lakewood, NJ) and 0.01 mg/mL DNase I (Sigma, St. Louis, MO) in DMEM for 1.5 hours at 37°C. Cells were pelleted by centrifugation at 1000 g for 8 minutes, resuspended in DMEM containing 20% BSA, and again pelleted. The microvessels in the pellet were digested with 1 mg/mL collagenase/dispase (Roche Diagnostics Operations Inc., Indianapolis, IN) and 0.1 mg/mL DNase I in DMEM for 1 hour at 37°C and separated on a 33% Percoll gradient (GE Healthcare, Waukesha, WI) by centrifugation. Isolated cells were washed in DMEM before plating on collagen-(Sigma) treated flasks in DMEM supplemented with 20% fetal bovine serum, 50 µg/mL gentamycin, 2 mmol/L glutamine, 100 µg/mL heparin, 100 µg/mL endothelial cell growth supplement, endothelial mitogen (Biomedical Technologies Inc, Stoughton, MA), and 4 µg/mL puromycin. After 48 hours, growth medium was changed to puromycinfree medium. Once confluent, cells were detached (0.05% trypsin-EDTA, Sigma) and plated on collagen-coated multiwell plates. Cells were passaged no more than once. Purity of the culture was confirmed by immunocytochemistry with antibodies against EC markers von Willebrand factor (1:50, Santa Cruz Biotechnology, Inc.), CD31 (1:50, BD Pharmingen), CD102 (1:100, BD Pharmingen, San Diego, CA), CD34 (1:50, Cedarlane), and glucose transporter 1 (1:1000, Abcam, Cambridge, MA). Cell images were taken on an inverted (Leica DFC 350FX, Leica, Wetzlar, Germany) or confocal (Zeiss 710, Zeiss, Oberkochen, Germany) microscope as shown in the Figure in the online-only Data Supplement. Purity of the culture was further confirmed by a negative reaction to vascular smooth muscle α-actin and glial fibrillary acidic protein. 
Drug Treatment

OGD/Reperfusion
ECs were subjected to OGD for 12 hours at 37°C in an anaerobic chamber (Coy Laboratory Products, Grass Lake, MI) filled with an anoxic gas mixture (5% CO 2 , 5% H 2 , and 90% N 2 ). The oxygen concentration was maintained at 0 parts per million using a palladium catalyst. Anoxic conditions were monitored continuously with an oxygen monitor (Oxygen-Hydrogen Gas Analyzer; Coy Laboratory Products) placed inside the chamber. To initiate OGD, growth medium was removed, cells were washed, and replaced with prewarmed, glucose-free DMEM. Cells were maintained in the OGD chamber for 12 hours. OGD was terminated by replacing OGD medium with prewarmed growth medium containing glucose and returning cultures to a normoxic incubator under 5% CO 2 /95% air at 37°C for reperfusion. Separate cultures in which growth medium was replaced with fresh medium but not subjected to OGD served as control.
Cell Death Assays
Cell viability was assessed by staining ECs with fluorescent markers for live (Calcein-AM, Invitrogen, Carlsbad ,CA) and dead (Propidium Iodide [PI], Sigma) cells. Briefly, 1 µL of reconstituted Calcein-AM solution (containing 50 µg of Calcein-AM in 250 µL of dimethyl sulfoxide) was added to each well of confluent EC culture in a 24-well plate and incubated at 37°C for 30 minutes. Fifteen minutes into the incubation, 0.75 µL of PI was added to each well. The cells were then examined under an inverted microscope, where live cells appeared fluorescent green (Calcein-AM) and dead cells were stained red (PI). Cell death was calculated from the ratio of PI-positive cells to the sum of PI-positive and Calcein-AM-positive cells counted under a fluorescent microscope (Nikon TE200, Nikon, Tokyo, Japan). Cell death was also assessed by immunolabeling ECs for cleaved caspase-3 (1:250; Cell Signaling Technology Inc, Danvers, MA).
Immunocytochemistry
Cells were fixed using 4% paraformaldehyde and blocked for 1 hour at room temperature in 5% normal donkey serum+1% BSA+0.1% TritonX-100 solution (Sigma Aldrich). Primary antibody, diluted as specified in blocking buffer, was applied and incubated overnight at 4°C. Coverslips were washed with PBS+0.1% Tween-20 (Sigma-Aldrich), and the secondary antibody was applied in blocking buffer for 2 hours at room temperature. Coverslips were washed and mounted on slides using Fluoromount-G mounting agent (Southern Biotech, Birmingham, AL).
TaqMan Real-Time Quantitative Polymerase Chain Reaction
RNA was isolated from ECs using RNAqueous-Micro kit (Ambion, Grand Island, NY) and reverse transcribed using the High Capacity cDNA Reverse Transcription Kit (ABI, Grand Island, NY); the resulting cDNA was amplified using TaqMan Universal polymerase chain reaction (PCR) amplification (ABI) in the ABI Prism 7000 sequence detection system (Applied Biosystems, Grand Island, NY). Quantitative PCR was performed in a 96-well plate using 50 µL total volume, with each sample run in triplicate. PCR was also run on controls in which the template had not been added to determine DNA contamination and primer-dimer formation. RNA that had not been reverse transcribed was also included to discount genomic DNA amplification. 18S was measured as an internal control using the 18S rRNA control kit-FAM-TAMRA (Eurogentec, Liege, Belgium). Commercially available EPHX2 primers (Eurogentec) were used.
EETs Assay
The concentration of EETs in primary ECs was determined by liquid chromatography-tandem mass spectrometry. Primary ECs cultured in 6-well plates were washed with PBS, scraped, and collected in PBS. The cell suspension was centrifuged at 14 000 g for 10 minutes at 4°C, and cell pellets were resuspended in 200 µL PBS, homogenized on ice with a microultrasonic cell disruptor at a setting of 6.5 (2-mm probe, highest setting 20, Sonic Dismembrator model 100, Fisher Scientific, Waltham, MA), hydrolyzed and extracted, then subjected to liquid chromatography-tandem mass spectrometry analysis using the 4000 Q-TRAP triple quadrupole mass spectrometer (Applied Biosystems, Foster City, CA) with electrospray ionization in negative mode. The instrument was interfaced with a Promi nence High Performance Liquid Chromatography unit (Shimadzu, Kyoto, Japan) which allowed pressures to 10 000 psi. Resolution was obtained with a 2.1×250 mm, 5 µ-BetaBasic C18 high performance liquid chromatography column with guard and gradient elution with water and acetonitrile (Thermo Scientific, Waltham, MA); both with 0.002% acetic acid under the following conditions: 45% to 60% B over 1 minute, linear to 65% B over 15 minutes, linear to 95% B over 0.10 minute, isocratic at 95% B for 4 minutes, linear to 45% B over 0.1 minute, and isocratic at 45% B for 10 minutes. Flow rate was 0.5 mL/min and column temperature was 40°C. Electrospray ionization source parameters included curtain gas 50, ion spray voltage −4000, temperature 550°C with ion source gas 1 and gas 2 at 50, and an entrance potential of -10 V. Samples were infused individually and instrument parameters were optimized for multiple reaction monitoring with selective transitions. The deuterated internal standard 14,15-EET-d 8 was spiked into each sample and monitored. The amount of EETs in the sample was calculated by calculating the ratio of the compound's peak area to that of 14,15-EETd 8 , then compared with a standard curve generated from blank hanks balanced salts spiked with known amounts of EETs.
ROCK Assay
ROCK activity in ECs was measured by a commercially available ROCK Activity Assay Kit (Cell Biolabs, San Diego, CA). Briefly, culture medium was aspirated off and ECs were washed with cold saline buffer, scraped, and homogenized in the presence of protease inhibitors (complete MINI, EDTA-free, protease inhibitor cocktail tablets, ROCHE, Mannheim, Germany). Cell homogenate was then applied to a strip well microtiter plate precoated with a recombinant myosin phosphatase target subunit 1. After incubation, the phosphorylation of myosin phosphatase target subunit 1 at its Thr696 residue by ROCK was detected by an antiphosphomyosin phosphatase target subunit 1 (Thr696) antibody and HRP-conjugated secondary antibody and read spectrophotometrically.
Hydrolase Activity Assay
Soluble epoxide hydrolase activity was determined using Epoxyfluor 7 (Cayman Chemical Company, Ann Arbor, MI; Jones et al 20 ) . ECs were lysed in PBS and immediately used for hydrolase activity quantification. Protein concentration of the lysate was determined using Biorad Protein Assay (Biorad, Hercules, CA). Hydrolase activity was assessed in 25 mmol/L BisTris-HCl (Sigma-Aldrich) solution containing 0.1 mg/mL BSA and 5 µmol/L Epoxyfluor 7 substrate incubated for 30 minutes at 37°C in a 96-well flat-bottomed plate (Corning, Corning, NY). Fluorescence of hydrolyzed Epoxyfluor 7 was determined using an excitation wavelength of 330 nm (bandwidth 20 nm) and emission 465 nm (bandwidth 20 nm) on a plate reader (VICTOR, Wallac/Perkin Elmer, Waltham, MA). Activity was normalized to sample protein concentration and expressed as relative fluorescence units.
Statistical Analysis
Statistically significant differences between groups were determined by a t test for 2 groups and ANOVA followed by Holm-Sidak post hoc analysis for multiple groups using the Sigmastat software (Systat Software Inc, Chicago, IL). All data were expressed as mean±SEM, with statistical significance set at P<0.05.
Results
To assess the sex difference in EC susceptibility to ischemic injury, ECs from male and female mouse cerebral vessels were subjected to 12 hours of OGD followed by 24 hours of reperfusion. Characterization of EC culture is shown in the Figure in the online-only Data Supplement. Cell death was measured both by PI staining and cleaved caspase-3 labeling and expressed as a percentage of total cells. At baseline, PI-positive cells constituted >1% of cells in both female and male cultures. OGD induced a significant increase in cell death, which was significantly lower in female than male ECs (17.0±1.8% versus 43.3±5.0%, respectively, n=7, P<0.05) ( Figure 1A) . At baseline, no cleaved caspase-3-positive cells were detected, however, after OGD male ECs exhibited significantly higher cell death than female cells (2.9±0.8% versus 0.48±0.3% respectively, n=4, P<0.05) ( Figure 1B) . The absolute levels of cell death vary between these 2 detection methods, although both show that cell death after OGD is higher in males compared with females. Figure 1B shows that cleaved caspase-3 labeling does not label all cells with condensed nuclei, hence accounting for this difference between PI labeling and cleaved caspase-3 labeling.
We tested the hypothesis that the differential sensitivity to ischemic injury between male and female ECs is linked to differences in EETs and sEH. Immunofluorescent labeling with anti-sEH antibody revealed more intense staining in male versus female ECs (Figure 2A, n=3 ). The sex difference was confirmed by measuring mRNA expression of EPHX2, the gene encoding for sEH, using TaqMan real-time quantitative PCR. Figure 2B shows that the level of EPHX2 mRNA was lower in female than male ECs at baseline (0.20±0.08 versus 0.64±0.18 relative to 18S RNA; n=4, P<0.05). After OGD, EPHX2 mRNA was reduced in both male and female ECs, but the difference remained statistically significant (0.45±0.11 in men versus 0.26±0.16 in women, n=4, P<0.05).
To determine whether lower sEH in F ECs results in higher EETs, the concentration of total EETs was measured by liquid chromatography-tandem mass spectrometry. Figure 2C demonstrates that female ECs had significantly higher levels of EETs compared with male EC at baseline (856.5±140.86 versus 272±102.33 pg/mL, n=4, P<0.05).
To determine whether differences in sEH expression and EETs levels contribute to the sex difference in sensitivity to ischemic injury, we pretreated male and female EC cultures with sEH inhibitor t-AUCB (1 µmol/L) or vehicle (dimethyl sulfoxide). t-AUCB was effective at inhibiting hydrolase activity by 31.15% (not shown). In agreement with Figure 1 , Figure 3A shows that vehicle-treated female ECs sustain significantly less damage compared with male ECs (9.0±0.99% versus 42.1±5.1%, n=7, P<0.05). Inhibition of sEH reduced cell death in both female and male ECs, abolishing the sex difference in cell death (3±0.7% in female versus 9.1±1.0% in male EC; n=5; P=0.47).
The results presented above suggest that EETs are protective against OGD-induced ischemic injury in EC damage. To directly test this hypothesis, we pretreated male and female ECs with 14,15-EET or vehicle (ethanol) before OGD. Figure 3B shows that 14,15-EET significantly reduced cell death in both female and male ECs (from 15.2±1.1% to 6.27±0.63% in female EC; n=7; P<0.05; and from 40.1±3.4% to 8.65±0.74%; n=7; P<0.05; compared with corresponding vehicle in male ECs).
Finally, we determined whether protection by EETs is linked to inhibition of ROCK activation after OGD. Figure 4A shows that ROCK activity was significantly increased after OGD and that this increase was more pronounced in male compared with female ECs (5.39±0.19 versus 2.95±0.53fold increase above baseline, respectively; n=3; P<0.05). Pretreatment with 14,15 EET inhibited OGD-induced ROCK activation in male ECs (from 5.39±0.19 to 1.32±0.03 folds; n=3; P<0.05) but not in female ECs (2.95±0.53 versus 3.36±0.19; n=3; P=0.51). To determine whether EC protection by ROCK inhibitors is sexually dimorphic, we treated male and female ECs with ROCK inhibitor Y-27632 (10 µmol/L) or vehicle (PBS) before, during, and after OGD. Figure 4B shows that ROCK inhibition reduced cell death in male ECs (from 45.4±5.53 to 25.6±3.8%; n=5; P<0.05 compared with corresponding vehicle) but not in female EC (16.8±1.8% versus 10.4±2.4%; n=5; P=0.0613). We also show that treating male cells with both 14,15-EET and Y-27632 does not result in further decrease in cell death after OGD compared with either treatment alone ( Figure 4C ) suggesting that the effects are not additive but that the 14,15-EET protection observed is mediated by ROCK inhibition. 
Discussion
We report three new findings: (1) Female mouse brain ECs are more resistant to ischemic injury induced by OGD than male ECs. (2) Reduced susceptibility of female ECs to ischemic injury is, in part, attributable to lower levels of expression of sEH and higher EETs. (3) Higher EETs in female ECs protect ECs, in part, by inhibiting OGD-induced ROCK activation.
Sex differences in ischemic brain injury and cerebrovascular regulation are observed in clinical and experimental studies. 1, 14, [21] [22] [23] An important determinant of brain tissue perfusion after cerebral ischemia is the integrity of ECs. Indeed, sex differences in EC function have previously been described between men and women 24 and in animals using isolated vessels and in vivo using preparations such as the cranial window. 14, 22 However, it is not clear from these studies whether sex differences are inherent to the endothelium or affected by surrounding cells and hormones. Furthermore, previous studies assessed baseline endothelium-dependent responses and did not evaluate sex differences in sensitivity to ischemic injury. Our study demonstrates for the first time that ECs from adult male and female mice exhibit an inherently different response to ischemic injury, with female ECs exhibiting higher resistance to ischemic damage than male cells. Given the importance of ECs in vascular reactivity, inflammation, the blood-brain barrier, and in angiogenesis, our findings suggest that inherent differences in EC susceptibility to ischemia may, in part, underlie the differences in acute vascular responses and recovery from injury observed between males and females.
The mechanism underlying the differential sensitivity of male and female ECs to ischemic injury is unknown. We tested the hypothesis that the difference is related to differences in epoxyeicosanoid signaling. EETs are arachidonic acid metabolites of cytochrome P450 epoxygenases that are produced in the brain by astrocytes and vascular endothelium. 13, 25 EETs have been shown to protect the brain from ischemic injury by multiple mechanisms, including vasodilatation, cytoprotection, and suppression of postischemic inflammation. 26 The cytoprotective effect of EETs after ischemia has been shown in cortical neurons and glial cells in vitro. 27 Whether this cytoprotection extends to cerebrovascular ECs has not been studied previously. In the peripheral vasculature, EETs in general, and 14,15-EETs in particular, are protective against EC apoptosis. 10 In our study, we make the novel observation that 14,15-EETs protect both female and male ECs from OGDinduced cell death.
The biological activity of EETs is terminated in vivo via metabolism by sEH. 12 Consistent with the protective function of EETs in cerebral ischemia and the role of sEH in regulating cellular EETs levels, 23 pharmacological inhibition or gene deletion of sEH reduces infarct size after experimental stroke in mice. 28, 29 Interestingly, earlier work from our group has shown that the cerebrovascular expression and activity of sEH in intact cerebral vessels are higher in male compared with female mice. 13 Whether this difference in sEH expression is attributable to the endothelium or vascular smooth muscle has not been determined. In this study, we show that differences in sEH expression and EETs levels are present in cerebral ECs and that these differences may underlie the observed differences in ischemia-induced cell death.
The mechanism of protection by EETs is multifactorial and involves membrane-associated and intracellular targets. In our study, we show that there are sex-specific differences in ROCK activation after OGD and link these differences to the inhibitory effect of endogenous EETs. We also demonstrate a novel therapeutic potential role of ROCK inhibitor Y-27632 by promoting EC survival. ROCK is the best characterized effector of rho, a member of the small GTPase family of proteins. Hypoxia-induced EC apoptosis has, in part, been attributed to activation of ROCK. 16 ROCK activation during apoptosis results in increased myosin activity, bundling of F-actin by activated myosin, actin-myosin contractile force generation, cell contraction, and ultimately cell blebbing. 30, 31 In a mouse model of middle cerebral artery occlusion, ROCK was activated in the ischemic region of the brain, and the inhibition of ROCK reduced cerebral infarct size and improved neurological deficit after middle cerebral artery occlusion. 32 In culture, inhibition of ROCK prevents ischemia-induced EC apoptosis, in part, by maintaining prosurvival phosphotidylinositol 3-kinase/Akt activity and preventing F-actin rearrangement. 16 In conclusion, the present study demonstrates that ECs isolated from female cerebral microvessels are more resistant to ischemic injury, in part, because of lower sEH expression and higher EETs levels, leading to stronger inhibition of ROCK activation after OGD in female compared with male ECs. These findings suggest that higher EETs signaling is an endogenous vasoprotective pathway in female EC survival after ischemic injury and identify a novel mechanism for ROCK-mediated vasoprotection. Given the critical role of the endothelium for proper brain function, EET signaling may represent a therapeutic target against cerebral endothelial dysfunction after ischemic stroke.
